SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Brune M) "

Sökning: WFRF:(Brune M)

  • Resultat 1-10 av 87
  • [1]234567...9Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Abelsson, J., et al. (författare)
  • The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
  • 2012
  • Ingår i: Bone Marrow Transplantation. - : Nature Publishing Group. - 1476-5365 .- 0268-3369. ; 47:3, s. 380-386
  • Tidskriftsartikel (refereegranskat)abstract
    • Between 1982 and 2009 a total of 92 patients with myelofibrosis (MF) in chronic phase underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) was given to 40 patients, and reduced intensity conditioning (RIC) was used in 52 patients. The mean age in the two groups at transplantation was 46 +/- 12 and 55 +/- 8 years, respectively (P<0.001). When adjustment for age differences was made, the survival of the patients treated with RIC was significantly better (P=0.003). Among the RIC patients, the survival was significantly (P=0.003) better for the patients with age <60 years (a 10-year survival close to 80%) than for the older patients. The type of stem cell donor did not significantly affect the survival. No significant difference was found in TRM at 100 days between the MAC-and the RIC-treated patients. The probability of survival at 5 years was 49% for the MAC-treated patients and 59% in the RIC group (P=0.125). Patients treated with RIC experienced significantly less aGVHD compared with patients treated with MAC (P<0.001). The OS at 5 years was 70, 59 and 41% for patients with Lille score 0, 1 and 2, respectively (P=0.038, when age adjustment was made). Twenty-one percent of the patients in the RIC group were given donor lymphocyte infusion because of incomplete donor chimerism, compared with none of the MAC-treated patients (P<0.002). Nine percent of the patients needed a second transplant because of graft failure, progressive disease or transformation to AML, with no significant difference between the groups. Our conclusions are (1) allo-SCT performed with RIC gives a better survival compared with MAC. (2) age over 60 years is strongly related to a worse outcome and (3) patients with higher Lille score had a shorter survival. Bone Marrow Transplantation (2012) 47, 380-386; doi:10.1038/bmt.2011.91; published online 9 May 2011
  •  
5.
  • Barkholt, L., et al. (författare)
  • Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
  • 2006
  • Ingår i: Annals of Oncology. - : Oxford University Press. - 1569-8041. ; 17:7, s. 1134-1140
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres. Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3-41) months. Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II-IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42-600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), < 3 metastatic sites (HR 2.61, P = 0.002) and a Karnofsky score > 70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%. Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score > 70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.
  •  
6.
  • Einarsdottir, S., et al. (författare)
  • Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation
  • 2021
  • Ingår i: Vaccine. - 0264-410X .- 1873-2518. ; 39:7, s. 1035-1038
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Our aim was to assess response and side effects of 4 doses of TBE vaccine to patients (pts) after allo- and autologous stem cell transplantation (SCT). PATIENTS: Included were 104 pts with leukaemia, myeloma and lymphoma, median age 61 yrs. METHODS: Vaccine (FSME-Immun (R)) was given at 9, 10, 12, and 21 months post-transplant. Serum samples were obtained before and after vaccinations. Healthy controls (n = 27) received 3 vaccinations. Assessments of TBE specific IgG antibodies were performed by Enzygnost anti-TBE ELISA test (Siemens, Sweden). Results: Antibody levels (>12 U/mL; "seropositivity") were seen in 77% and 80% of pts after allo- and autoSCT; IgG levels; 89 vs 94 U/mL. Ongoing chronic GvHD and immunosuppression (n = 29) was associated with sero-negativity in the last sample (p = 0.007). All controls (n = 27) developed protective antibody levels. Conclusions: TBE vaccination was safe, and 4 doses starting 9 months post-SCT, induced seropositivity in a vast majority of pts. (C) 2021 Elsevier Ltd. All rights reserved.
  •  
7.
  • Hoglund, Martin, et al. (författare)
  • Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
  • 2013
  • Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 122:7, s. 1284-1292
  • Tidskriftsartikel (refereegranskat)abstract
    • Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 87
  • [1]234567...9Nästa
Typ av publikation
tidskriftsartikel (57)
konferensbidrag (29)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (61)
övrigt vetenskapligt (26)
Författare/redaktör
Brune, M. (62)
Ljungman, P (29)
Brune, Mats, 1950 (16)
Lenhoff, S. (12)
Ringden, O (12)
Hoglund, M (12)
visa fler...
Lehmann, S (11)
Wahlin, A (11)
Juliusson, G (10)
Remberger, M. (9)
Mollgard, L (9)
Einarsdottir, S (8)
Lazarevic, V (8)
Brune, Mats (8)
Isaksson, C. (7)
Lenhoff, Stig (7)
Niederwieser, D (7)
Andreasson, B (6)
Martino, R (6)
Juliusson, Gunnar (6)
Barkholt, L (6)
Anderson, H (6)
Blaise, D (6)
Brinch, L. (5)
Malm, C. (5)
Remes, K. (5)
Mattsson, J. (5)
Ljungman, Per (5)
Winiarski, J (5)
Carlson, K (5)
Höglund, Martin (5)
Helstrom, L (5)
Bregni, M. (5)
Sandstedt, A. (5)
Finke, J. (4)
Malm, Claes (4)
Maeurer, M (4)
Tidefelt, U (4)
Hellstrand, Kristoff ... (4)
Demirer, T (4)
Lehmann, Sören (4)
Goransson, M. (4)
Socie, G (4)
Andersson, Per Ola (4)
Simonsson, B (4)
Möllgård, Lars (4)
Stenke, L (4)
Peccatori, J. (4)
Pedrazzoli, P. (4)
Siena, S. (4)
visa färre...
Lärosäte
Karolinska Institutet (49)
Göteborgs universitet (21)
Lunds universitet (12)
Linköpings universitet (11)
Uppsala universitet (7)
Umeå universitet (6)
visa fler...
RISE (3)
Örebro universitet (2)
Jönköping University (2)
Chalmers tekniska högskola (2)
Stockholms universitet (1)
visa färre...
Språk
Engelska (87)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (30)
Naturvetenskap (5)
Teknik (3)
Lantbruksvetenskap (3)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy